Adamas (ADMS) Parkinson's Disease Drug Positive In Phase III
Zacks Investment Research | Sep 20, 2016 10:28PM ET
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced positive data from the phase III study – EASE LID 3 – on its lead wholly owned candidate, ADS-5102 extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD). We expect investors to react positively to the news.
Data from the study demonstrated a statistically significant reduction in LID at 12 weeks in patients receiving ADS-5102, compared with placebo, as assessed by the Unified Dyskinesia Rating Scale (UDysRS). The candidate was safe and generally well tolerated. The study met its primary endpoint. Results were presented at the World Parkinson Congress in Portland.
In addition, Adamas Pharma announced positive post-hoc analysis of data from the EASE LID study on ADS-5102. Results from the study showed an improvement in activities of daily living (ADLs) in PD patients.
The company is presently conducting an open-label safety study – EASE LID 2 – which is open to patients from EASED, EASE LID and EASE LID 3, and LID patients who have undergone deep brain stimulation. Patients in the study will be followed for up to two years.
Meanwhile, Adamas Pharma expects to file a New Drug Application (NDA) for ADS-5102 for the treatment of LID later this year.
ADAMAS PHARMA Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.